# US 2025/0144185 A1 · Enzymatic Methods for Treating Neurodegenerative Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144185 A1
- Document ID: US20250144185A1
- Status: Published application
- Kind: A1
- Application number: 19/014,130
- Filed: 2025-01-08
- Published: 2025-05-08
- Earliest claimed: 2023-03-17
- Assignees: Biome-ase Research, LLC
- Applicants: Biome-ase Research, LLC
- Inventors: Ghania Ait GHEZALA; Ariane MENDEN
- Web page: https://patentgrep.com/patent/US20250144185A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Y 301/01003: Triacylglycerol lipase (3.1.1.3)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present disclosure relates to methods for treating, managing, or reducing the severity of one or more neurodegenerative disorders by administration of Candida rugosa lipase (CRL) to a patient in need thereof. The present disclosure also relates to pharmaceutical compositions comprising CRL for treating, managing, or reducing the severity of one or more neurodegenerative disorders. The present disclosure also relates to dietary supplements comprising CRL for improving memory and/or cognitive function in a subject in need thereof.

## Claims

### Claim at position 1

1-58. (canceled)

### Claim 59

A method for improving cognitive function in a subject in need thereof, comprising administering a dietary supplement comprising Candida rugosa lipase (CRL) to the subject in need thereof.

### Claim 60 (depends on 59)

The method of claim 59, wherein the cognitive function of the subject in need thereof is assessed by a Montreal Cognitive Assessment (MoCA), a Mini-Mental State Exam (MMSE), a Mini-Cog, or any combination thereof.

### Claim 61 (depends on 60)

The method of claim 60, wherein the cognitive function of the subject in need thereof is assessed by a MoCA.

### Claim 62 (depends on 61)

The method of claim 61, wherein the MoCA score of the subject in need thereof is 26 or more after the administering.

### Claim 63 (depends on 60)

The method of claim 60, wherein the cognitive function of the subject in need thereof is assessed by a MMSE.

### Claim 64 (depends on 63)

The method of claim 63, wherein the MMSE score of the subject in need thereof is 24 or more after the administering.

### Claim 65 (depends on 60)

The method of claim 60, wherein the cognitive function of the subject in need thereof is assessed by a Mini-Cog.

### Claim 66 (depends on 65)

The method of claim 65, wherein the Mini-Cog score of the subject in need thereof is 3, 4, or 5 after the administering.

### Claim 67 (depends on 59)

The method of claim 59, wherein the cognitive function of the subject in need thereof is assessed by CNS Vitals, a Symbol Digit Modalities Test (SDMT), a Profile of Mood States (POMS), a Pittsburgh Sleep Quality Index (PSQI), a Multidimensional Fatigue Inventory Questionnaire (MFI-20), a Frontal Systems Behavioral Scales (FrSBe), or any combination thereof.

### Claim 68 (depends on 59)

The method of claim 59, wherein the subject in need thereof exhibits improved cognition after the administering.

### Claim 69 (depends on 68)

The method of claim 68, wherein the improved cognition comprises an enhanced ability to encode, store, and retrieve information.

### Claim 70 (depends on 68)

The method of claim 68, wherein the improved cognition comprises a reduction in memory loss, a reduction in memory impairment, or both.

### Claim 71 (depends on 59)

The method of claim 59, wherein the administering is for a period of 1 month to 5 years.

### Claim 72 (depends on 59)

The method of claim 59, wherein the dietary supplement is in tablet form or capsule form.

### Claim 73 (depends on 72)

The method of claim 72, wherein the dietary supplement comprises about 30,000 Fédération International Pharmaceutique (FIP) units of CRL per tablet or capsule.

### Claim 74 (depends on 73)

The method of claim 73, wherein the administering comprises administration of one or two tablets of the dietary supplement per day.

### Claim 75 (depends on 73)

The method of claim 73, wherein the administering comprises administration of one or two capsules of the dietary supplement per day.

### Claim 76 (depends on 59)

The method of claim 59, wherein the improved cognitive function in the subject in need thereof persists for a time period of at least 6 months.

### Claim 77 (depends on 59)

The method of claim 59, wherein the improved cognitive function in the subject in need thereof persists for a time period of at least one year.

### Claim 78 (depends on 59)

The method of claim 59, wherein the improved cognitive function in the subject in need thereof persists for a time period of at least 2 years.
